“Biomarker-driven cancer therapies are changing the paradigm of pharmaceutical and biotechnology industry. To keep up with the current trend, our company is developing first-in-class anticancer drugs that could predict the drug’s efficacy before administering to the patients”, said Dong-Hoon Jin.

Link: https://www.hankyung.com/it/article/201909052443f